J Bacteriol Virol.  2019 Dec;49(4):203-211. 10.4167/jbv.2019.49.4.203.

Antiviral Activity of Gemcitabine Against Echovirus 30 Infection in Vitro

  • 1Department of Beauty Science, Kwangju Women's University, 165 Sanjeong-dong, Gwangsan-gu, Gwangju 62396, Korea.
  • 2Laboratory of Microbiology and Immunology, College of Pharmacy, Kangwon National University, Chuncheon 24341, Korea.
  • 3Department of Clinical Pathology, Daejeon Health Institute of Technology, Daejeon 34504, Korea. kayun@hit.ac.kr


Echovirus 30 is one of the major causes of meningitis in children and adults. The purpose of our current study was to investigate whether selected antiviral drugs could provide antiviral activity against echovirus 30. Using RD cells, we assessed the cytopathic effect of echovirus 30, including viral RNA levels as indicators of viral replication. The effects of gemcitabine were compared to rupintrivir, a well-known antiviral drug. To understand the activity gemcitabine exerts on the viral life cycle, time course and time-of-addition assays were implemented. The most effective compounds against echovirus 30 were gemcitabine and rupintrivir, as demonstrated by their concentration-dependent activity. Gemcitabine affects the early stages of echovirus 30 infection by disrupting viral replication. However, gemcitabine failed to directly inactivate echovirus 30 particles or impede viral uptake into the RD cells. Gemcitabine can be considered as a lead candidate in the development of echovirus 30 antiviral drugs, specifically in the early stages of echovirus 30 replication.


Echovirus 30; Gemcitabine; Early stages

MeSH Terms

Antiviral Agents
Enterovirus B, Human*
In Vitro Techniques*
Life Cycle Stages
RNA, Viral
Antiviral Agents
RNA, Viral
Full Text Links
  • JBV
export Copy
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error